← Leaderboards
Mingtao Zeng
University Of Rochester
$4,705,531
Attributed
$4,705,531
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $625.8K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,705,531 · 8
By mechanism
R21$2,806,275 · 5
R01$1,115,984 · 1
R15$625,772 · 1
R03$157,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- William J Bowers$3,529,197
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentImmunizationLaboratory MouseVaccinesEnzyme Linked Immunosorbent AssayInfluenzaCellsMouse ModelVaccinationNonhuman Therapy EvaluationWestern BlottingsTransfection /Expression VectorPublic Health RelevanceAnimalsPolymerase Chain ReactionProteinsAmino AcidsAnthrax Lethal FactorDesignContainmentAnthrax DiseaseCommunicable DiseasesEdemaInfluenza Virus Vaccine
Grant awards (21)
New Nasal Spray Influenza Vaccine for Children$480,000
R15 · FY2023 · HD · contact PI
New Nasal Spray Influenza Vaccine for Children (Research Supplement for Post Baccalaureate Diversity Candidate)$145,772
R15 · FY2023 · HD · contact PI
New Therapeutic Influenza Vaccine Created by Host Cell-Restricted Attenuation$229,500
R21 · FY2018 · AI · contact PI
New Therapeutic Influenza Vaccine Created by Host Cell-Restricted Attenuation$191,250
R21 · FY2017 · AI · contact PI
Targeted-delivery of small interference RNA against anthrax$229,500
R21 · FY2016 · AI · contact PI
Targeted-delivery of small interference RNA against anthrax (1 R21 AI118228-01A1)$56,792
R21 · FY2016 · AI · contact PI
Targeted-delivery of small interference RNA against anthrax$191,250
R21 · FY2015 · AI · contact PI
New Vaccine against Influenza$363,862
R01 · FY2011 · AI · contact PI
New Vaccine against Influenza$367,538
R01 · FY2010 · AI · contact PI
New Vaccine against Influenza$384,584
R01 · FY2009 · AI · contact PI
Development of a New Tularemia Vaccine$304,668
R21 · FY2006 · AI · contact PI
Development of a New Tularemia Vaccine$312,000
R21 · FY2005 · AI
New genetic vaccine to protect aganist botulism$315,000
R21 · FY2004 · AI
Genetic immunization against pneumococcal disease$196,875
R21 · FY2004 · DC
Genetic immunization against pneumococcal disease$49,502
R21 · FY2004 · DC
New genetic vaccine to protect aganist botulism$315,000
R21 · FY2003 · AI
Genetic immunization against pneumococcal disease$196,875
R21 · FY2003 · DC
Multi-component and easily administrated anthrax vaccine$78,750
R03 · FY2003 · AI
Genetic immunization against pneumococcal disease$21,188
R21 · FY2003 · DC
Genetic immunization against pneumococcal disease$196,875
R21 · FY2002 · DC
Multi-component and easily administrated anthrax vaccine$78,750
R03 · FY2002 · AI